{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282059","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.553513+00:00","generated_at":"2026-06-21T23:46:23.992346+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ikena Oncology reports initial IK-175 clinical data: 20% ORR in combination with nivolumab in urothelial carcinoma","bullets":["IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.","Monotherapy: 10% ORR, 20% DCR; one confirmed partial response with duration of response 14.9 months and ongoing.","Dose escalation in solid tumors: prolonged stable disease up to >19 months; MTD not reached; 1200mg selected as expansion dose.","Well tolerated with low-grade rash, nausea (monotherapy) and fatigue, dysgeusia (combo); only 2 serious adverse events.","Program in collaboration with Bristol Myers Squibb; opt-in decision eligible through early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282059","json":"https://secwatch.observer/filing/0001193125-22-282059.json","markdown":"https://secwatch.observer/filing/0001193125-22-282059.md","text":"https://secwatch.observer/filing/0001193125-22-282059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/0001193125-22-282059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/d410137d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:46:23.992346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}